16 results about "Helper t-cells" patented technology

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and / or one or more CD4+ helper T cell recognition epitopes, which is / are derived from the antigen. The antigen-loaded nanogel is administered at least one day prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.

The application discloses a use of ursolic acid as a SARS-CoV-2 subunit vaccine adjuvant, aims to solve the technical problems of relatively weak immunogenicity of existing subunit vaccines, possible local or systemic adverse reactions of some adjuvants and unclear action mechanism, and provides a new medical use of ursolic acid. The ursolic acid can effectively improve the antigen-specific antibody level of the subunit vaccine immunized mice, promote the formation of germinal centers and enhance follicular helper T cell response. The action mechanism is that after the ursolic acid is combined with PTPRF, the stability of the PTPRF is affected and the degradation of the PTPRF is promoted, thereby enhancing the downstream STAT3 phosphorylation, promoting the expression of antigen presentation related genes and improving the antigen presentation ability of the dendritic cells, and finally enhancing the antibody response of the body. The application provides a new subunit vaccine adjuvant candidate molecule for preventing severe SARS-CoV-2 related infections in clinic, and provides a new molecular target and mechanism basis for the development of subunit vaccine adjuvants.

The invention discloses application of valeriana jatamansi jones. The valeriana jatamansi jones are derived from dry roots and rhizomes of valeriana jatamansi jones, and the valeriana jatamansi jones can regulate cell balance of CD4 < + > helper T cells in a human immune system so as to relieve colon tissue pathological damage and mucoprotein secretion abnormality. The traditional Chinese medicine composition can protect the colon tissue pathological injury and mucous membrane layer of the UC mouse, repair the colon pathological injury, regulate and control the balance of intestinal immune cells, and is high in safety coefficient.

The present application relates to cancer immunotherapy, for example, T cell stimulation mediated anti-tumor therapy. Accordingly, disclosed herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating a cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs) that induce Type I helper T cell (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.

The present application belongs to the technical field of genetic engineering, and particularly relates to a bovine rotavirus group A multi-epitope fusion protein and application thereof. The present application provides a bovine rotavirus group A multi-epitope peptide, fusion protein based on ferritin nanocarriers and application thereof. The multi-epitope peptide is based on bovine rotavirus group A VP4 and VP7 protein sequences, and highly conserved and strong immunogenicity cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes are screened by using immunoinformatics technology, and are spliced to form a multi-epitope fusion antigen with good conformational stability. Immunological evaluation shows that the multi-epitope fusion antigen has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and fusion protein can induce the body to produce high-level neutralizing antibodies against multiple genotypes of BRVA G6, G8 and G10, and significantly improve the broad spectrum and durability of immunoprotection.

The invention belongs to the field of immunology, and particularly relates to a method for regulating directional differentiation of helper T cell 17 (Th17) and application of the method. The method for regulating and controlling the directional differentiation of the Th17 cells into the Th1 cells is provided firstly, specifically, the activity of a nucleolus composite pore associated protein 4 gene is inactivated or reduced, so that the directional differentiation of the Th17 cells into the Th1 cells is influenced. The invention also provides a pharmaceutical composition, which is a protein and / or a compound and / or RNA for inhibiting the gene function of the gene for directionally differentiating the helper T cell 17 into the Th1 cell. According to the application, the differentiation trend of Th17 to Th1 cells is regulated and controlled on the translation level by knocking out the Noc4L gene by utilizing the regulation and control function of the nucleolus composite pore associated protein 4 in the Th17 cells. The application can provide a new way and means for developing novel nucleic acid drugs to treat autoimmune diseases caused by inflammatory cytokines.

The invention relates to the technical field of biology, in particular to a CD4 / TGF-beta1 binding bispecific antibody which at least comprises a first protein functional area and a second protein functional area, the first protein functional area comprises a first antigen binding site targeting CD4, the first antigen binding site can bind to the 77th site, the 79th site, the 96th site, the 121st-124th site of polypeptide shown as SEQ ID NO: 19, and the second antigen binding site can bind to the 124th-124th site of polypeptide shown as SEQ ID NO: 19. The 127th to 134 amino acids and the 163rd amino acids; and the second protein functional region comprises a second antigen binding site targeting TGF beta 1. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with the TGF beta 1 and is not combined with the TGF beta 2 and the TGF beta 3, so that cardiotoxicity caused by the TGF beta 2 and the TGF beta 3 is avoided. The invention has the effect of preparing medicines for preventing and treating fatty liver.

The invention provides a method for detecting peripheral helper T cells expressing IL-5, IL-13 and IL-21 in peripheral blood with a non-diagnostic or therapeutic purpose, and belongs to the technical field of cell detection. The method provided by the invention fills the blank of Tph cell detection methods related to the type 2 inflammatory response. According to the method, the total Tph cells are obtained through flow type sorting, and then in-vitro stimulation is carried out to detect marker expression in the cells, so that the content of Tph cells related to the type 2 inflammatory response is obtained. According to the method for detecting the intracellular marker by firstly separating the Tph cells and then treating the Tph cells, interference on subsequent detection of the Tph cells due to change of expression of the cell surface marker caused by direct treatment of the PBMC cells can be avoided. In addition, the fluorescent dye selected by the intracellular marker has strong fluorescence, so that positive and negative cells can be better distinguished, and the detection sensitivity is high.

The present invention relates to an immunologic adjuvant comprising poly (beta-hydroxybutyrate) nanoparticles, and a vaccine composition comprising the poly (beta-hydroxybutyrate) nanoparticles. The nanoparticles based on the non-cytotoxicity and obtaining the FDA approved substance not only have no cytotoxicity and high biosafety, but also can make up for the disadvantages of BHB. Unlike existing commercialized immunologic adjuvants, the present invention is a novel nanoscale immunologic adjuvant based on a substance derived from a living body, which is versatile with respect to antigens having a protein form, not limited to specific antigens, and has the convenience of being able to function in the form of a single mixture. Furthermore, the present invention can also be used as a base material for a next-generation immunologic adjuvant, which effectively enhances humoral immunity and cellular immunity at the same time by functionally increasing the activity of antigen presenting cells (APC) and by inducing the activity of follicular helper T cells (follicular helper T cells) and the activity of germinal center B cells (germinal center B cells).

The invention discloses a Brucella multi-epitope fusion protein, a vaccine, a preparation method and application, the Brucella multi-epitope fusion protein is designed based on a Brucella WbkC protein, a B cell epitope (LBL), a cytotoxic T cell epitope (CTL) and a helper T cell epitope (HTL) of the Brucella multi-epitope fusion protein are screened, and the Brucella multi-epitope fusion protein is prepared by connecting KK, AAY, GPGPG and GGGGS connecting peptides. A vaccine prepared from the fusion protein provided by the invention can provide better antigen-specific immune response than WbkC for immunizing mice. Therefore, the subunit fusion protein vaccine involved in the invention is expected to become a novel brucella vaccine, and has good application and development prospects.

The present invention relates to the field of adoptive immune cell therapies, such as adoptive T cell therapies. It provides immune cells, such as gamma delta T cells, CD4 helper T cells, mucosa-related constant cells, innate lymphocytes, NK cells, macrophages, or other types of immune cells, or combinations thereof, engineered to express CD8 co-receptors, and it provides advantageous recombinant configurations of nucleic acids encoding CD8 alpha beta co-receptors and alpha beta TCR constructs, wherein the nucleic acid comprises a construct capable of mediating the expression of CD8 [alpha] and CD8 [beta] chains and of a TCR [alpha] chain construct and of a TCR [beta] chain construct under the control of a promoter. This improves adoptive immune cell therapy, e.g., it may improve the function and persistence of engineered immune cells. The immune cells can express an MHC I restricted alpha beta TCR construct as well as a CD8 co-receptor. Pharmaceutical compositions comprising the cells or nucleic acids are also provided. These are useful for the treatment of cancer or infectious diseases.